Monday, 16 November 2026European Markets

Europe's Biotech Exposure Is Narrow but Real: A Swedish Royalty Stream Grows While the AI Funding Mood Sours

BioArctic's Leqembi royalty rose about 10 percent to SEK 179 million in Q2 2026, and Vor Bio reported strong Phase 3 kidney data. Meanwhile a $1 trillion tech selloff hit the funding mood. We checked each figure against its source and flag where the evidence is weak.

Via News Editorial Team

November 15, 2026

This article was generated by AI. Built from the source documents listed below. How we work

Europe's Biotech Exposure Is Narrow but Real: A Swedish Royalty Stream Grows While the AI Funding Mood Sours
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

The European piece is small, and it is already earning

Most of this week's biotech news is American. The one clearly European revenue story in our verified material comes from Stockholm. BioArctic AB (publ), headquartered in Stockholm1 and partnered with Eisai1, said its royalty on Leqembi (lecanemab) came to SEK 179 million for the second quarter of 2026, up approximately 10 percent on the same quarter of 2025.2 Eisai reported global Leqembi sales of JPY 29.3 billion for the period.2

The headline growth understates the underlying picture, according to the company. The second quarter of 2025 included a one-time stockpiling effect in China of around JPY 5.3 billion. BioArctic says that excluding it, royalty revenues in Q2 2026 grew approximately 43 percent year-over-year.2 In its own words: "Excluding the stockpiling effect, royalty revenues in Q2 2026 grew approximately 43 percent compared to the same quarter last year."2

Two things are worth keeping apart. The 43 percent figure is the company's adjusted number, stated in a press release distributed through NewsEOD, a feed whose checked claims held up 54 percent of the time across 6,663 tested.2 That is better than a coin flip but not a guarantee, so we treat the adjustment as BioArctic's framing, not as audited fact. The SEK 179 million and 10 percent are the plainer figures, and they come from the same release.

Where the dossier is thin: it does not tell us what share of BioArctic's total income this royalty is, nor anything about EU regulatory decisions on Leqembi. We will not guess at either.

One European personnel signal

On 1 November 2026, Idorsia appointed Begoña Carreño-Gómez as Chief Business Development Officer and a member of its Executive Committee.3 The dossier says nothing more about strategy. A business development hire often points toward dealmaking, but that is our reading, not a statement from the company.

The clinical progress is real, mostly outside Europe

Vor Bio (Nasdaq: VOR), a Boston-based company, announced final two-year results from the Phase 3 TELIGAN trial of telitacicept in IgA nephropathy, a kidney disease. Treated patients showed an annualized eGFR slope of -0.6, against -5.7 mL/min/1.73 m²/year for placebo, a treatment difference of 5.1 (p<0.001). The company also reports 89 percent and 81 percent reductions in the risk of confirmed 30 percent and 40 percent declines in kidney function, with proteinuria reductions sustained through 104 weeks and a favorable safety profile.4 These are company-reported results; independent review will matter.

Scribe Therapeutics reported third quarter 2026 results on 12 November. Its first-in-human Phase 1 trial of STX-1150, an epigenetic silencing therapy for LDL cholesterol lowering, continues to enrol, with initial clinical data expected in the first half of 2027. The company also expanded a collaboration with Sanofi.5 Scribe argues that current LDL-C therapies are limited by poor persistence, with studies showing 50 percent to 70 percent of patients stop treatment within one year.5 It also says people with naturally occurring PCSK9 loss-of-function variants have been reported to have 28 percent lower mean LDL-C and up to 88 percent lower coronary heart disease risk, and that STX-1150 aims to mimic this protection.5 That is a hypothesis from the developer, and the human data are still ahead of us. Our topic summary also cites a cash figure of $174.2 million for Scribe, but the source excerpt we hold does not confirm it, so we do not rely on it.

AI-designed viruses: an early, single data point

Radical Numerics says AI-designed viruses have treated the startup's first patient, with an experimental treatment targeting drug-resistant E. coli.6 This is one patient, reported by the company and relayed by a newsletter. That newsletter source has a weak measured record: only 6 percent of 16 checked claims held up.6 Treat it as an announcement, not as evidence of efficacy.

The funding backdrop turned colder

On 30 October 2026 a $1 trillion tech selloff deepened fears of an AI bubble, as big AI bills and weak earnings spooked investors. The Nasdaq 100 had its worst day since June.7 The next day OpenAI cut its funding target by $10 billion.8 On 1 November Binance users withdrew $3.6 billion when the exchange reopened after a hack.9 To picture the first number: $1 trillion wiped from tech in a few sessions is more than the annual output of many mid-sized national economies, though the dossier gives no ranking, so we use it only as a sense of scale.

For European biotech, the link is indirect and our own inference. Companies that depend on investors willing to fund AI-flavoured stories may find that money harder to raise. Nothing in the dossier shows a European biotech failing to raise capital this month.

What a strong balance sheet looks like: Incyte

Incyte Corporation, headquartered in Wilmington, Delaware1, is not European, but its filings give us the cleanest verified numbers in this piece. Cash was $1.69 billion at fiscal year-end 2024 and $3.10 billion at fiscal year-end 2025, close to a doubling.10 It stood at $3.98 billion in Q2 2026 and $3.28 billion in Q3 2026.10 Cost of revenue rose each year: $255.0 million in FY2023, $312.1 million in FY2024 and $372.1 million in FY2025.10 Earnings per share were $2.65 in FY2023.10 Capital expenditure is listed at an identical $48.7 million for both FY2024 and FY2025.10 We report that as filed and draw no conclusion from the match.

Incyte develops Jakafi, Opzelura, pemigatinib and ruxolitinib phosphate cream.1 The dossier does not include the pancreatic cancer data named in our topic, so we cannot assess it here.

A caution on weak sources

Some claims in the dossier should not carry weight. Generation Lab says its treatment "blocks the systemic spread of aging in the bloodstream, reawakens the body's own repair mechanism and restores health and youth to multiple tissues."11 That is the company's fact sheet language, relayed by MIT Technology Review, and the writer notes being approached as a "longevity influencer".11 Our reliability measure for that feed is 6 percent of 16 checked claims. Likewise, a stock-comparison article on AbbVie and Eli Lilly comes from a source whose checked claims held up 31 percent of the time across 58.12 We therefore make no claim about Lilly demand here.

What to watch

  • BioArctic's next royalty report: does the underlying growth the company describes persist once the China stockpiling comparison drops out?2
  • Scribe's first STX-1150 clinical data, expected in the first half of 2027.5
  • Whether the AI and crypto funding stress spreads: OpenAI's reduced target and the Binance outflows are the early markers.8,9
  • Incyte's cash trend after the Q2 to Q3 2026 step down.10

Source documents

Via News is a conduit. We point to the source documents behind this report: we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score12 source documents12 with a live linkVerifiability: Strong
  1. [1]News articleMotley Fool
    AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026?
  2. [2]News articleYahoo Finance· October 15, 2026
    Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner
  3. [3]News articleMIT Technology Review
    A startup claims it’s found a drug to make your blood young
  4. [4]News articleYahoo Finance· July 27, 2026
    OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results
  5. [5]News articleYahoo Finance· July 29, 2026
    Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026
  6. [6]News articleYahoo Finance· November 12, 2026
    Scribe Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
  7. [7]News articleYahoo Finance· October 22, 2026
    Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy
  8. [8]News articleMIT Technology Review
    The Download: AI’s trillion-dollar gamble and OpenAI’s biology data bid
  9. [9]News articleMIT Technology Review
    The Download: a secretive antiaging drug and joining virtual power plants
  10. [10]News articleMIT Technology Review
    The Download: computing’s next leap and permafrost’s climate threat
  11. [11]Press releaseGlobeNewswire· July 15, 2026
    Three Biotechs Deliver Catalysts to Watch
  12. [12]News articleNasdaq· July 29, 2026
    Top Biotech Gainers: KNSA Soars On Q2 Results, TRIB, OPK On Watch, MPLT On The Mend?

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

  1. Built from 12 source documents from 5 publications, dated 15 Jul 2026 to 12 Nov 2026
  2. Published 15 Nov 2026
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›
Via News Editorial Team

The Via News Editorial Team writes analysis and news from the Via News source-traceability system, under the editorial responsibility of L. Miguel Salvado, Editor. Each article is built only from source documents we hold and lists them at the end, so every claim can be checked. Articles generated with AI say so under the byline, as the EU AI Act requires.